Activated long-term peripheral blood cultures as preparation for adoptive alloreactive cell therapy in cancer patients

Shoshana Morecki, Yael Gelfand, Sarit Levi, Arnon Nagler, Reba Condiotti, Corinne Nabet, Aliza Ackerstein, Shimon Slavin

Research output: Contribution to journalArticlepeer-review

Abstract

Different modes of in vitro activation of peripheral blood mononuclear cells (PBMC) were compared for their effect on long-term propagation. PBMC cultures were activated by short exposures to the mitogen phytohemagglutinin (PHA) and the CD3 complex, with or without secondary signals provided by ligands of CD28 costimulatory molecules. Activation and long-term cultures were carried out in the presence of recombinant interleukin-2 (rIL-2). Addition of supernatant derived from IL-2-activated PBMC improved culture cell yield. Cumulative fold expansions ranged between 103 and 105 within 21 days. The highest cell yield was found after PHA activation. Fewer cells were obtained after activation with a combination of CD3 and CD28, and even fewer were obtained after CD3 activation alone. An increase in CD8+ and CD56+ cells, without change in CD4+ cells, was found in activated cultures when compared with fresh PBMC. Non-MHC-restricted cytotoxic activity was documented in all activated cultures. Cytotoxic activity per culture was highest in PHA-activated PBMC because of the high cell yield on the day of harvest. Successful in vitro expansion of PBMC might be helpful for gene transfer into T lymphocytes, as well as for the induction of an antitumor response, particularly for prevention and treatment of relapse of hematologic malignancies following allogeneic or autologous bone marrow transplantation.

Original languageEnglish
Pages (from-to)115-124
Number of pages10
JournalJournal of Hematotherapy and Stem Cell Research
Volume6
Issue number2
DOIs
StatePublished - Apr 1997
Externally publishedYes

Fingerprint

Dive into the research topics of 'Activated long-term peripheral blood cultures as preparation for adoptive alloreactive cell therapy in cancer patients'. Together they form a unique fingerprint.

Cite this